🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Leukemia

Clinical Study Protocol of Maintenance Therapy With Venetoclax in Elderly Patients With AML in First Complete Remission NCT05909293NA1 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: Venclexta 100 MG Oral Tablet Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia NCT05281809Phase 21 site📍 Pittsburgh John Lister · Tests: Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous) Registry of Myelodysplastic Syndromes and Therapy-related Acute Myeloid Leukemia NCT06956755n/a1 site📍 Rouen Groupe Francophone des Myelodysplasies Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia NCT05827549Phase 210 sites📍 Daegu📍 Daejeon📍 Hwasun Ho Joon Im · Tests: Reinduction(4weeks), Cosolodation 1st(3weeks), Consolidation 2nd(3weeks), Blinatumomab 1st(High Risk Group)_4 Weeks, Bl… Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention NCT06686108Phase 21 site📍 Shanghai Shanghai General Hospital, Shanghai Jiao Tong University Sc… · Tests: Azacitidine (AZA) Days 1 - 5, Decitabine (DAC), Venetoclax Evaluation of Combined Sensitising and Hypomethylating Therapy Outcomes in AML PDX NCT06782971n/a4 sites📍 Canberra📍 Sydney📍 Sydney Clinical Hub for Interventional Research (CHOIR) Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia NCT05506332Phase 12 sites📍 Edegem📍 Roeselare University Hospital, Antwerp · Tests: Venetoclax, 6-mercaptopurine Chemogenomic Profiling in Hematological Malignancies (HEM-Profiling 2021) NCT07445984NA1 site📍 Parma Azienda Ospedaliero-Universitaria di Parma · Tests: Genetic, molecular and/or omics analyses Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML NCT05024552Phase 11 site📍 Tampa H. Lee Moffitt Cancer Center and Research Institute · Tests: Gilteritinib, Vyxeos CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies NCT07106749Phase 11 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: CD180 CART Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies NCT07284433Phase 1, Phase 213 sites📍 Chicago📍 Evanston📍 Providence AvenCell Therapeutics, Inc. · Tests: Cyclophosphamide (Non-IMP, Lymphodepletion), Fludarabine (Non-IMP, Lymphodepletion), Allo-QuadCAR01-T JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia NCT06689917NA1 site📍 Wuhan Tongji Hospital · Tests: JY231 Injection Nurture by Nature Feasibility Study NCT07780123NA1 site📍 Frederiksberg Ina Olmer Specht · Tests: Nature-base intervention Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse NCT06928662Phase 1, Phase 21 site📍 Seattle Fred Hutchinson Cancer Center · Tests: Decitabine, Bone Marrow Aspiration, Bone Marrow Biopsy, Chest Radiography, Cytarabine Donor Derived CD117 CAR-T Cells in the Treatment of R/R Acute Myeloid Leukemia NCT07144020EARLY Phase 11 site📍 Hangzhou Zhejiang University · Tests: CD117 CAR T-cells CAV Regimen for R/R Ph- B-ALL NCT05657652NA1 site📍 Suzhou The First Affiliated Hospital of Soochow University · Tests: cladribine, cytarabine,venetoclax A Phase 1b Study of Lonitoclax + Azacitidine in Acute Myeloid Leukemia Patients NCT07303660Phase 16 sites📍 Moscow📍 Krasnogorsk📍 Velikiy Novgorod Lomond Therapeutics Holdings, Inc. · Tests: ZE50-0134, Azacitidine Days 1-7, ZE 50-0134 Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome NCT00801489Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Cytarabine, Decitabine, Filgrastim-sndz, Fludarabine Phosphate, Gemtuzumab Ozogamicin A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies NCT05908409Phase 1, Phase 211 sites📍 Santander📍 Salamanca📍 Barcelona IDP Discovery Pharma S.L. · Tests: IDP-121 Pediatric Orthopaedic Implant Safety & Efficacy NCT05361980n/a1 site📍 Vancouver University of British Columbia · Tests: Pediatric orthopaedic implant HVA vs IA/DA or VA in the Treatment of ND HR-AML NCT06810791Phase 31 site📍 Guangzhou Nanfang Hospital, Southern Medical University · Tests: HVA, VA, Standard Chemotherapy A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia. NCT06566742Phase 22 sites📍 Miami📍 Houston M.D. Anderson Cancer Center · Tests: Olutasidenib Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial NCT06355583Phase 28 sites📍 Birmingham📍 Leeds📍 London Imperial College London · Tests: EBX-102, Placebo Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies NCT06508775NA7 sites📍 Berlin📍 Cologne📍 Erlangen Miltenyi Biomedicine GmbH · Tests: MB-CART19.1, MB-CART20.1, MB-CART2019.1 Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL) NCT07572136Phase 11 site📍 Bethesda National Cancer Institute (NCI) · Tests: TSLPR-CART, Cyclophosphamide, Fludarabine Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL NCT06481228NA1 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: CAR-T cells, Venetoclax, Olverembatinib KSV01 Injection as the Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia NCT07246707Phase 11 site📍 Hangzhou Zhejiang University · Tests: KSV01 Injection Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia NCT04793919Phase 231 sites📍 Brussels📍 Prague📍 Aarhus N Associazione Italiana Ematologia Oncologia Pediatrica · Tests: Mylotarg, Arsenic Trioxide, All-trans retinoic acid Blinatumomab Consolidation in Real World NCT07117136n/a5 sites📍 Jacksonville📍 Chicago📍 Chicago Medical College of Wisconsin Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML NCT05807932Phase 1, Phase 26 sites📍 Aachen📍 Düsseldorf📍 Cologne Heinrich-Heine University, Duesseldorf · Tests: Venetoclax, Amsacrine, Ara-C, Tacrolimus, Mycophenolate Mofetil
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy